|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM371672325 |
| 003 |
DE-627 |
| 005 |
20240726232312.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240429s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202404645
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1482.xml
|
| 035 |
|
|
|a (DE-627)NLM371672325
|
| 035 |
|
|
|a (NLM)38678386
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xin, Jingrui
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Fluorinated Organic Polymers for Cancer Drug Delivery
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.07.2024
|
| 500 |
|
|
|a Date Revised 25.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a In the realm of cancer therapy, the spotlight is on nanoscale pharmaceutical delivery systems, especially polymer-based nanoparticles, for their enhanced drug dissolution, extended presence in the bloodstream, and precision targeting achieved via surface engineering. Leveraging the amplified permeation and retention phenomenon, these systems concentrate therapeutic agents within tumor tissues. Nonetheless, the hurdles of systemic toxicity, biological barriers, and compatibility with living systems persist. Fluorinated polymers, distinguished by their chemical idiosyncrasies, are poised for extensive biomedical applications, notably in stabilizing drug metabolism, augmenting lipophilicity, and optimizing bioavailability. Material science heralds the advent of fluorinated polymers that, by integrating fluorine atoms, unveil a suite of drug delivery merits: the hydrophobic traits of fluorinated alkyl chains ward off lipid or protein disruption, the carbon-fluorine bond's stability extends the drug's lifecycle in the system, and a lower alkalinity coupled with a diminished ionic charge bolsters the drug's ability to traverse cellular membranes. This comprehensive review delves into the utilization of fluorinated polymers for oncological pharmacotherapy, elucidating their molecular architecture, synthetic pathways, and functional attributes, alongside an exploration of their empirical strengths and the quandaries they encounter in both experimental and clinical settings
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a cancer therapy
|
| 650 |
|
4 |
|a drug packaging
|
| 650 |
|
4 |
|a fluoropolymer
|
| 650 |
|
4 |
|a polymer nanoparticle
|
| 650 |
|
4 |
|a synthesis method
|
| 650 |
|
7 |
|a Polymers
|2 NLM
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 700 |
1 |
|
|a Lu, Xue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cao, Jimin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Weihui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Qian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Deping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Xin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ding, Dan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 30 vom: 19. Juli, Seite e2404645
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:30
|g day:19
|g month:07
|g pages:e2404645
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202404645
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 30
|b 19
|c 07
|h e2404645
|